Ignite Creation Date:
2024-05-06 @ 3:23 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02271139
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2017-03-09
First Post:
2014-10-17
Brief Title:
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase ALK-Rearranged Non-Small Cell Lung Cancer NSCLC After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
Sponsor:
Organization:
Genentech Inc